SELLAS Life Sciences Group Inc buy tbackenh
Start price
05.07.16
/
50%
€19,213
Target price
18.10.16
€27,060
Performance (%)
-60.56%
End price
18.10.16
€7,576.8
Summary
This prediction ended on 18.10.16 with a price of €7,576.8. Massive losses of -60.56% were the result for the BUY prediction by tbackenh. tbackenh has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | 7.327% | 7.327% | -27.151% | -85.469% |
| iShares Core DAX® | -0.612% | 0.567% | 12.585% | 14.838% |
| iShares Nasdaq 100 | -3.018% | -3.205% | 26.208% | 38.328% |
| iShares Nikkei 225® | -2.647% | 0.330% | 9.482% | 5.652% |
| iShares S&P 500 | -1.932% | -1.126% | 23.191% | 38.791% |
Comments by tbackenh for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
Galena Biopharma
Eigentlich wollte ich ja nicht mehr...
Bei Galena Biopharma sieht der Chart mega-interessant aus, hohe Vola, Chance auf Verdopplung. Natürlich ist vieles undurchsichtig, aber einen kleinen Zock ist es schon wert.
(Vom Mitglied beendet)